生物可吸收激素释放植入物用于鼻窦口的安全性与有效性:一项随机临床试验
该前瞻性、多中心、随机对照试验采用患者内对照设计,纳入80例慢性鼻窦炎(CRS)患者,在双侧额窦开放术后,随机在一侧额窦口(FSO)放置含370 µg莫米松糠酸酯的沙漏形生物可吸收激素释放植入物,对侧仅手术。结果显示,植入侧第30天需术后干预的比例显著低于单纯手术侧(11.5% vs 32.8%),且炎症评分和再狭窄/闭塞率均显著降低,疗效持续至第90天,未观察到植入物相关不良事件。
要点
- 沙漏形生物可吸收激素释放植入物可安全放置于额窦口。
- 植入侧第30天需术后干预比例显著低于单纯手术侧。
- 植入侧炎症和再狭窄/闭塞率显著降低,疗效持续至第90天。
核心结论
- 在术后未使用其他立即局部皮质类固醇的情况下,沙漏形激素释放鼻窦植入物安全且比单纯手术更有效地维持额窦口通畅并改善手术结局。
研究设计与样本
- 前瞻性、多中心、随机临床试验,采用患者内对照设计,共纳入80例成人慢性鼻窦炎患者,来自美国12个中心,研究时间为2015年7月至2016年3月。
- 患者平均(SD)年龄49.5(13.4)岁,其中男性53例(66%),女性27例(34%)。
- 所有患者接受双侧额窦开放术,随机选择一侧额窦放置激素释放植入物,对侧仅手术。
主要发现
- 第30天,独立盲法评审评估显示,植入侧需术后干预的比例为11.5%,单纯手术侧为32.8%,平均差异为-21.3%(95% CI,-35.1%至-7.6%)。
- 第30天,临床研究者实时内镜评估显示,植入侧需术后干预的平均差异为-17.3%(95% CI,-27.9%至-6.7%),炎症评分平均差异为-12.3 mm(95% CI,-18.3至-6.4 mm),额窦再狭窄或闭塞率平均差异为-22.7%(95% CI,-33.5%至-11.9%)。
- 疗效持续至第90天:需术后干预的平均差异为-11.7%(95% CI,-21.0%至-2.4%),额窦口再狭窄和/或闭塞的平均差异为-17.4%(95% CI,-28.6%至-6.1%)。
- 未观察到植入物相关不良事件。
关键数值与推荐
- 植入物为沙漏形生物可吸收激素释放植入物,含370 µg莫米松糠酸酯。
- 主要结局指标为第30天额窦口需术后干预(药物或手术)的情况,由独立盲法外科医生基于视频内镜 findings 判定。
- 次要结局包括第30天和第90天内镜评分以及第90天计算机断层扫描。
临床怎么用
- 对于接受内镜鼻窦手术的慢性鼻窦炎患者,在额窦口放置该激素释放植入物可减少术后干预需求、减轻炎症并降低再狭窄/闭塞风险。
- 该获益是在术后未使用其他立即局部皮质类固醇的条件下观察到的,临床决策时需结合实际术后用药方案。
局限性
- 研究采用患者内对照设计,可能引入局部效应或全身吸收的混杂影响。
- 样本量为80例,随访至第90天,长期疗效和安全性未评估。
- 研究期间术后未使用其他立即局部皮质类固醇,结论外推至常规使用术后激素的患者需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Suboptimal outcomes of endoscopic sinus surgery (ESS) are often associated with restenosis and inflammation of frontal sinus ostia. Steroid-releasing sinus implants have been shown to maintain sinus patency by minimizing inflammation and scar tissue formation. An hourglass-shaped, bioabsorbable, steroid-releasing implant was developed to provide mechanical support and optimize drug delivery to paranasal sinus ostia. OBJECTIVE: To assess the safety and efficacy of the hourglass-shaped, bioabsorbable, steroid-releasing sinus implant in improving postoperative outcomes when placed in the frontal sinus ostia (FSO) following ESS in patients with chronic rhinosinusitis (CRS). DESIGN, SETTING, AND PARTICIPANTS: In a prospective, multicenter, randomized clinical trial using an intrapatient control design (ESS followed by implant placement within 1 FSO vs ESS alone on the contralateral side) 80 adult patients, with a mean (SD) age of 49.5 (13.4) years and consisting of 53 (66%) men and 27 (34%) women, were enrolled and underwent bilateral frontal sinusotomies with 1 frontal sinus randomized to receive a steroid-releasing implant. The study was carried out in 12 US centers between July 2015 and March 2016. INTERVENTIONS: A bioabsorbable steroid-releasing implant with hourglass shape containing 370 µg of mometasone furoate. All patients received standardized postoperative care. MAIN OUTCOMES AND MEASURES: The need for postoperative interventions, medical and surgical, in the FSO at day 30, as determined based on review of video endoscopic findings by an independent blinded surgeon. Also, endoscopic grading by the independent reviewer and clinical investigators at day 30 and day 90 and computed tomographic scan at day 90. RESULTS: The mean (SD) age of patients was 49.5 (13.4) years, 53 (66%) were men. Implants were successfully placed in all 80 randomized treatment sinuses. At day 30, steroid-releasing implants significantly reduced the need for postoperative interventions to 11.5% compared with 32.8% by surgery alone (mean difference, -21.3%; 95% CI, -35.1% to -7.6%), as assessed by the independent reviewer. Real-time endoscopic assessment by clinical investigators at day 30 demonstrated significant reduction in need for postoperative intervention (mean difference, -17.3%; 95% CI, -27.9% to -6.7%), significant reduction in inflammation score (mean difference, -12.3 mm; 95% CI, -18.3 to -6.4 mm), and significant reduction in rate of frontal restenosis or occlusion (mean difference, -22.7%; 95% CI, -33.5% to -11.9%) on treated compared with control sides. The results favoring the treatment sides were sustained through day 90: reduced need for postoperative interventions (mean difference, -11.7%; 95% CI, -21.0% to -2.4%) and reduction in restenosis and/or occlusion of the frontal ostium (mean difference, -17.4%; 95% CI, -28.6% to -6.1%). No implant-related adverse events were observed. CONCLUSIONS AND RELEVANCE: The hourglass-shaped steroid-releasing sinus implant was safe and more effective in maintaining FSO patency and improving surgical outcomes compared with surgery alone in the setting where no other immediate postoperative corticosteroids were administered. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02266810.
引用
- Luong A, Ow RA, Singh A, et al. Safety and Effectiveness of a Bioabsorbable Steroid-Releasing Implant for the Paranasal Sinus Ostia: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2017. PMID: 29098299. doi:10.1001/jamaoto.2017.1859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。